Ieq Capital LLC Buys 87,469 Shares of Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Ieq Capital LLC has significantly increased its stake in Xeris Biopharma by 129.2%, owning approximately 155,184 shares valued at around $852,000.
• Multiple hedge funds, including R Squared Ltd and MIRAE ASSET GLOBAL, have also boosted their holdings in Xeris Biopharma during the first quarter.
• Analysts have upgraded Xeris Biopharma's rating, with Wall Street Zen and Leerink Partners recognizing the stock's potential and providing target price increases.

Ieq Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 129.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,184 shares of the company's stock after acquiring an additional 87,469 shares during the quarter. Ieq Capital LLC owned approximately 0.10% of Xeris Biopharma worth $852,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of Xeris Biopharma by 38.7% during the fourth quarter. Wells Fargo & Company MN now owns 79,036 shares of the company's stock valued at $268,000 after purchasing an additional 22,050 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $45,000. MetLife Investment Management LLC increased its stake in shares of Xeris Biopharma by 47.7% during the fourth quarter. MetLife Investment Management LLC now owns 87,432 shares of the company's stock valued at $296,000 after acquiring an additional 28,224 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Xeris Biopharma by 5.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock valued at $578,000 after acquiring an additional 9,506 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $67,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Friday. HC Wainwright initiated coverage on Xeris Biopharma in a research report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price target for the company. Finally, Leerink Partners lifted their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $7.08.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch purchased 25,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Johnson sold 107,500 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total value of $786,900.00. Following the completion of the sale, the director directly owned 833,483 shares in the company, valued at approximately $6,101,095.56. This represents a 11.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,232 shares of company stock worth $1,430,777 in the last three months. Corporate insiders own 4.56% of the company's stock.

Xeris Biopharma Price Performance

NASDAQ:XERS traded up $0.03 during trading hours on Monday, reaching $7.88. The company's stock had a trading volume of 119,484 shares, compared to its average volume of 2,517,248. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -37.59 and a beta of 0.12. Xeris Biopharma Holdings, Inc. has a one year low of $2.51 and a one year high of $8.03. The business's 50-day moving average is $6.19 and its 200-day moving average is $5.15.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.